全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
-  2017 

MMP28在膀胱癌中的表达及其临床意义 MMP28 Expression in Blander Cancer and Its Clinical Significance

Keywords: MMP28,膀胱癌,预后

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的:探讨MMP28在膀胱癌中的表达情况及其与临床分期、组织学分级、预后等指标的关系,分析MMP28表达对膀胱癌预后的影响。方法:收集8对新鲜的膀胱癌组织及其配对的正常膀胱组织和173例膀胱癌组织蜡块,分别采用qRT-PCR和免疫组化法检测MMP28的表达,结合相关病理和随访指标,采用χ2检验、Kaplan-Meier法、Cox回归进行统计分析。结果:在转录水平上,膀胱癌组织的MMP28表达高于正常的膀胱癌组织,有统计学意义。MMP28蛋白在膀胱癌中的表达与其年龄、病理分级、临床分期有关(P=0.039,P=0.024,P=0.003),与性别、肿瘤数量、肿瘤直径无关(P=0.120,P=0.266,P=0.462)。膀胱癌中MMP28蛋白高表达组的总体生存率和无进展生存率显著低于低表达组(P=0.002,P=0.001)。单因素分析发现影响膀胱癌患者预后的因素有患者的年龄(P=0.006,P=0.007)、病理学分级(P=0.008,P=0.006)、肿瘤数目(P=0.012,P=0.013)、临床分期(P=0.003,P=0.003)和MMP28蛋白的表达(P=0.002,P=0.001)。而且,多因素分析表明只有临床分期(P=0.022,P=0.043)、MMP28(P=0.037,P=0.045)是预测膀胱癌总体生存和无进展生存的独立因素。结论:MMP28在膀胱癌中的表达是明显上调的。MMP28表达与膀胱癌的年龄较大、高组织分级、较晚临床分期、预后差呈正相关,是预测膀胱癌生存的一个独立因素,可能成为膀胱癌治疗的一个新靶点

References

[1]  Bister VO,Salmela MT,Karjalainen-Lindsberg ML,et al.Differential expression of three matrix metalloproteinases,MMP-19,MMP-26,and MMP28,in normal and inflamed intestine and colon cancer[J].Dig Dis Sci,2004,49(4):653-661.
[2]  Saarialho-Kere U,Kerkela E,Jahkola T,et al.Epilysin(MMP28)expression is associated with cell proliferation during epithelial repair[J].J Invest Dermatol,2002,119(1):14-21.
[3]  Lin MH,Liu SY,Su HJ,et al.Functional role of matrix metalloproteinase-28in the oral squamous cell carcinoma[J].Oral Oncol,2006,42(9):907-913.
[4]  Lohi JL,Wilson CL,Roby JD,et al.Epilysin:A novel human matrix metalloproteinase(MMP28)expressed in testis and keratinocytes and in response to injury[J].J Biol Chem,2001,276:1 013-1 014.
[5]  Momohara S,Okamoto H,Komiya K,et al.Matrix metalloproteinase 28/epilysin expression in cartilage from patients with rheumatoid arthritis and osteoarthritis:comment on the article by Kevorkian et al[J].Arthritis Rheum,2004,50(12):4 074-4 075.
[6]  Marchenko GN,Strongin AY.MMP28,a new human matrix metalloproteinase with an unusual cysteineswitch sequence is widely expressed in tumors[J].Gene,2001,265,87-93.
[7]  Bister VO,Salmela MT,Karjalainen-Lindsberg ML,et al.Differential expression of three matrix metalloproteinases,MMP-19,MMP-26,and MMP28,in normal and inflamed intestine and colon cancer[J].Dig Dis Sci,2004,49(4):653-661.
[8]  Li QL,Illman SA,Wang HM,et al.Matrix metalloproteinase-28transcript and protein are expressed in rhesus monkey placenta during early pregnancy[J].Mol Hum Reprod,2003,9(4):205-211.
[9]  Illman SA,Lehti K,Keski-Oja J,et al.Epilysin(MMP28)induces TGF-beta mediated epithelial to mesenchymal transition in lung carcinoma cells[J].J Cell Sci,2006,119(Pt 18):3 856-3 865.
[10]  Illman SA,Lohi J,Keski-Oja J.Epilysin(MMP28)-structure,expression and potential functions[J].Exp Dermatol,2008,17(11):897-907.
[11]  Sorsa T,Tjderhane L,Salo T.Matrix metalloproteinases(MMPs)in oral diseases[J].Oral Diseases,2004,10(6):311-318.
[12]  Siegel RL,Miller KD,Jemal A.Cancer statistics,2015[J].CA Cancer J Clin,2015,65:5-29.
[13]  Wen DG,Shan BE,Zhang SW,et al.Incidence and mortality rates of bladder cancer in registration areas of China from 2003to 2007[J].Tumor,2012,32(4):256-262.
[14]  Kamat AM,Dickstein RJ,Messetti F,et al.Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guerin therapy for bladder cancer:results of a prospective trial[J].J Urol,2012,187:862-867.
[15]  Grossman HB,Soloway M,Messing E,et al.Surveillance for recurrent bladder cancer using apoint-of-care proteomic assay[J].JAMA,2006,295:299-305.
[16]  Massova I,Kotra LP,Fridman R,et al.Matrix metalloproteinases:structures,evolution,and diversication[J].FASEB J,1998,12:1 075-1 095.
[17]  Illman SA,Keski-Oja J,Lohi J.Promoter characterization of the human and mouse epilysin(MMP28)genes[J].Gene,2001,275(1):185-194.
[18]  Mott JD,Werb Z.Regulation of matrix biology by matrix metalloproteinases[J].Curr Opin Cell Biol,2004,16:558-564.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133